- Home
- FISV vs GH Comparison
FISV vs GH Comparison
Compare FISV & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FISV | GH |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 22.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FISV | GH |
|---|---|---|
| Price | $46.01 | $177.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 19 |
| Target Price | ★ $146.17 | $119.79 |
| AVG Volume (30 Days) | ★ 6.6M | 1.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.84 | 6.74 |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $21,193,000,000.00 | $982,021,000.00 |
| Revenue This Year | N/A | $33.30 |
| Revenue Next Year | $3.94 | $28.27 |
| P/E Ratio | $20.78 | ★ N/A |
| Revenue Growth | 3.60 | ★ 32.88 |
| 52 Week Low | $45.13 | $60.46 |
| 52 Week High | $70.41 | $183.51 |
Technical Indicators
Market Signals| Indicator | FISV | GH |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 58.91 |
| Support Level | N/A | $153.88 |
| Resistance Level | $55.49 | $183.51 |
| Average True Range (ATR) | 1.67 | 7.78 |
| MACD | -0.35 | 0.44 |
| Stochastic Oscillator | 15.41 | 76.42 |
Price Performance
Historical ComparisonAbout FISV Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.